Sildenafil and AMD

Active ingredient in Viagra appears to offer safe and simple method for ocular treatment

Sildenafil and AMD
Sean Henahan
Sean Henahan
Published: Tuesday, May 1, 2018
D Jackson Coleman
Sildenafil, better known as the active ingredient in Viagra, appears to offer a safe and simple method for treating age-related and vitelliform macular degeneration and central serous retinopathy, according to new research presented at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting, in Honolulu, Hawaii. Researchers at Columbia University Medical Center enrolled 10 patients with macular disease. Patients received a low oral dose, 20mg per day of sildenafil, the dose used to treat pulmonary arterial hypertension. This is far lower than the dose used to treat erectile dysfunction. Patients underwent spectral domain optical coherence tomography, colour fundus photography and visual acuity testing. “We saw no loss of vision over a 30-month follow-up period. The data from this small study suggest that this could a nice way to treat ischaemia in these patients,” D Jackson Coleman MD, Professor of ophthalmology at Columbia University, New York, told EuroTimes. The most significant result observed was the maintenance or improvement in the photoreceptor layer in a patient with Best vitelliform macular dystrophy. That patient also had a significant improvement in visual acuity. A patient with central serous retinopathy also showed early and significant improvement, he reported. Sildenafil inhibits phosphodiesterase-5 and phosphodiesterase-6 in the choroid which increases choroidal perfusion. The drug also promotes oxidative metabolism, which decrease lipid biosynthesis, he explained.
Latest Articles
ESCRS Today 2025: Happy Anniversaries!

ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.

Read more...

ESCRS Today 2025: A Congress for Everyone

From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.

Read more...

ESCRS Today 2025: All Eyes on Innovation

Watching out for obstacles and opportunities

Read more...

Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Read more...

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Read more...

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Read more...

Supplement: ESCRS Clinical Trends Series: Presbyopia

Read more...

Debate: FS-LASIK or KLEx for Hyperopia?

FS-LASIK has more of a track record, but KLEx offers advantages.

Read more...

Four AI Applications Ready for Practice

Commercial offerings may save time, improve practice and research.

Read more...

Perioperative Medication Regimens for Cataract Surgery

Randomised controlled clinical trial results provide evidence-based guidance.

Read more...